The World Anti-Doping Agency (WADA) is pleased to announce that it has coordinated the simultaneous introduction of identical hematology analyzers at all throughout the world to further enhance precision and consistency of doping controls carried out as part of the .
These Sysmex XN-1000 automated hematology analyzers, which are operational globally from today (3 June), produce results that are more comparable and traceable over time.
WADA Senior Executive Director, Sciences and International Partnerships, Dr. Olivier Rabin, said: “This is another significant step forward in the ongoing development of the ABP program around the world. In running the ABP, it is extremely important to ensure that the results of tests taken over time from athletes who move around the world can be compared and monitored with a high degree of accuracy and comparability, regardless of the testing location.
“Importantly, these hematology analyzers function with a high degree of sensitivity and reproducibility. To date, Sysmex has actively supported WADA in the implementation of the ABP program.”
Senior Executive Officer, Managing Director and Head of Global Marketing for Sysmex Corporation, Iwane Matsui said: “We are honored to be in partnership with WADA, supporting its steadfast commitment to eradicating doping and to fostering fair sport. The proven precision and reliability of the XN-1000, as well as its proprietary quality control service and robust support structure, will deliver globally comparable and highly reliable results that will support higher-quality, more efficient and more streamlined ABP operations globally.”
Blood samples taken from athletes as part of the ABP program are analyzed at 30 WADA-accredited or approved around the world. The ABP was introduced in 2009 to monitor variations of athletes’ blood parameters over time, indirectly revealing blood manipulations – a method that complements conventional doping controls, which test directly for banned substances.